Cannabis Extracts Showed Anti-SARS-CoV-2 Activity, but Other Compounds Interfered

Only the neutral (decarboxylated) extracts containing CBD or THC as predominant cannabinoids showed antiviral activity against SARS-CoV-2, with all IC50 values below 10.0 micromolar. However, certain phenolic acids (salicylic acid, chlorogenic acid, ferulic acid) and flavonoids (abietin, luteolin) antagonized the antiviral activity in some genotypes.

Ethanolic extracts from seven high-CBD and two high-THC Cannabis sativa genotypes were prepared in both acidic (non-decarboxylated) and neutral (decarboxylated) forms. Phytochemical profiling used LC-UV, GC-MS, and LC-MS/MS. Dose-response antiviral assays against SARS-CoV-2 were performed, with correlation analyses between constituent levels and activity.

While cannabis as a COVID treatment is not clinically viable, understanding which plant compounds enhance or block antiviral activity informs broader pharmaceutical efforts. The finding that other plant compounds can antagonize cannabinoid effects has implications for whole-plant versus isolate product design.

The entourage effect (the idea that whole-plant cannabis works better than isolated compounds) is often assumed to be universally positive. This study provides a concrete example where other plant compounds actually reduced the primary cannabinoid's activity, challenging the assumption that more compounds always means better outcomes.

In vitro antiviral activity does not predict clinical efficacy. SARS-CoV-2 assay conditions may not reflect physiological cannabinoid concentrations. Correlation-based identification of antagonistic compounds needs direct validation. Only ethanolic extracts tested; other preparation methods may differ.